19. November 2009 04:02
Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.
[More]
50ccea28-a9bb-4b4c-9116-c045d0269177|0|.0
Posted in: Medical Science News | Medical Condition News
Tags: Biomarker, Breast Cancer, Cancer, Cell, Cell Proliferation, Cervical Cancer, Colon Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Oncogene, Ovarian Cancer, Radiotherapy, Renal Cell Carcinoma, Small Cell Lung Cancer, Sorafenib, Tamoxifen, VEGF
19. November 2009 01:37
Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.
[More]
93413953-874e-4748-8590-f191a2cb10c2|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Anesthesiology, Angiogenesis, Brain, Cancer, Cell, Cell Proliferation, Constipation, Life Expectancy, Lung Cancer, Metastasis, Morphine, Non-Small Cell Lung Cancer, Prostate Cancer, Small Cell Lung Cancer
19. November 2009 00:22
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.
[More]
9f19f465-9b09-4558-8717-5dc5f9c0f5b8|0|.0
Posted in: Drug Trial News | Pharmaceutical News
Tags: Anorexia, Biopsy, Biotechnology, Cancer, Cell, Cell Proliferation, Chemotherapy, Colorectal Cancer, Diarrhea, Erlotinib, Head and Neck Cancer, Hepatocellular Carcinoma, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Pfizer, Radiotherapy, Small Cell Lung Cancer, Squamous Cell Carcinoma, Vomiting
18. November 2009 09:19
Roche Applied Science announces the availability of the new CIM-Plate 16 for their xCELLigence System for cell analysis, for use in cancer research. The 16-well culture plate features electronic sensors for the direct study of cell migration and invasion on the xCELLigence RTCA DP Instrument.
[More]
18. November 2009 07:38
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.
[More]
2e16dd3c-6f4f-44b3-9889-330f4bb7656d|0|.0
Posted in: Drug Trial News | Pharmaceutical News
Tags: Blood Vessel, Cancer, Cell, Cell Proliferation, Hepatocellular Carcinoma, Hypercholesterolemia, microRNA, Nanoparticle, Oncology, Physiology, RNAi Therapeutics, siRNA, VEGF, Virus
17. November 2009 07:35
Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.
[More]
a1f7ad01-51ab-49e4-b5f8-42264963fa09|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Angiogenesis, Cancer, Cell, Cell Proliferation, Hepatitis B, Hepatocellular Carcinoma, Kidney Cancer, Kinase Inhibitor, Liver Cancer, Multiple Sclerosis, Nexavar, Oncology, Sorafenib
16. November 2009 10:47
Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.
[More]
f3aba2b0-84f6-4e58-a90b-5057d67253a0|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Biotechnology, Bone, Bone Marrow, Cancer, Cell, Cell Proliferation, Hematology, Insulin, Kinase Inhibitor, Oncology, Rapamycin
16. November 2009 10:21
Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."
[More]
ff0dced7-006e-4a03-a98a-cf8c7f078101|0|.0
Posted in: Men's Health News | Drug Trial News
Tags: Apoptosis, Bone, Cancer, Cell, Cell Proliferation, Chemotherapy, Diabetes, Diabetes Mellitus, Dihydrotestosterone, Oncology, Prostate Cancer, Steroid, Type 2 Diabetes
12. November 2009 03:30
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.
[More]
b08d0117-d867-4ae3-b9a3-eaeb29e7f0b4|0|.0
Posted in: Medical Science News
Tags: Acute Lymphoblastic Leukemia, Antibody, Arthritis, Asthma, Biomarker, Cancer, Cell, Cell Proliferation, Diabetes, Leukemia, Obesity, Oncogene
11. November 2009 00:24
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.
[More]
2a9c5c1b-a300-4337-9787-61d952dfe335|0|.0
Posted in: Medical Science News | Medical Condition News
Tags: Apoptosis, Cancer, Cell, Cell Proliferation, Chemotherapy, Cisplatin, DNA, Growth Hormone, Lung Cancer, Oncology, Radiotherapy, Small Cell Lung Cancer
10. November 2009 00:26
Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs. Now it may be possible to identify which patients are more likely to survive by analyzing the activity of hundreds of genes involved in the immune response and gene proliferation, according to researchers at NYU Langone Medical Center.
[More]
3d8e9797-f3b5-4b1f-89f7-d82ddc80f218|0|.0
Posted in: Medical Science News | Medical Condition News
Tags: Biopsy, Cancer, Cardiovascular Disease, Cell, Cell Proliferation, Dermatology, DNA, Education, Hospital, Immunotherapy, Infertility, Melanoma, Neurosurgery, Pathology, Pediatrics, Plastic Surgery, Skin Cancer, Transplant, Urology
6. November 2009 04:38
What is the role of proteins called polycystins in patients with polycystic kidney disease? A team of researchers from CNRS and INSERM, led by Eric Honoré from the Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, Université de Nice Sophia Antipolis/CNRS) has elucidated the molecular and cellular mechanisms linked to polycystin malfunctions that cause this common hereditary disease.
[More]
3. November 2009 23:32
Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments.
[More]
3. November 2009 06:15
Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments.
[More]
2. November 2009 10:11
Gilead Sciences, Inc., in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).
[More]
05fa345c-5c4b-44a1-8e30-4fc8a5acfe58|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Abdominal Pain, Anemia, Cell, Cell Proliferation, Cirrhosis, Constipation, Contraception, Copper, Dyspnea, Edema, Education, Endothelin, Exercise, Headache, Heart Failure, Jaundice, Nausea, Pregnancy, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Sinusitis, Sperm, Vomiting, Warfarin
Subscribe